Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
18 nov. 2024 07h30 HE
|
Incyclix Bio
INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be evaluated as part of ongoing Phase 1/2 study...
Incyclix Bio Expands Board of Directors with Appointment of Norman E. Sharpless, MD
12 nov. 2024 07h30 HE
|
Incyclix Bio
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
Incyclix Bio Announces Abstract Accepted for Presentation at 2024 San Antonio Breast Cancer Symposium
04 nov. 2024 07h30 HE
|
Incyclix Bio
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
20 août 2024 07h30 HE
|
Incyclix Bio
RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer
28 févr. 2023 07h30 HE
|
Incyclix Bio
– INX-315 is a novel, potent and selective inhibitor of CDK2 with compelling pre-clinical efficacy and safety data– First-in-human, Phase 1/2 study of INX-315 in patients with ER+/HER2- breast...
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
31 mars 2022 07h30 HE
|
Incyclix Bio
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital to join Incyclix Bio’s board of directors RESEARCH...